Assessment of Duodopa® effects on quality of life of patients with advanced Parkinson's disease and their caregivers

Rosella Ciurleo, Francesco Corallo, Lilla Bonanno, Viviana Lo Buono, Giuseppe Di Lorenzo, Roberta Versaci, Cettina Allone, Placido Bramanti, Silvia Marino

Research output: Contribution to journalArticle

Abstract

The gold standard of treatment in Parkinson's disease (PD) is levodopa/carbidopa whose long-term use induces motor and non-motor fluctuations and dyskinesias. Continuous infusion of intrajejunal levodopa/carbidopa intestinal gel (Duodopa®) reduces motor and non-motor symptoms and dyskinesias, and improves the quality of life of patients. The aim of this open observational prospective study was to evaluate the impact of Duodopa® on conditions of PD patients and caregivers, and their quality of life. We enrolled 12 patients with advanced PD and their caregivers. The PD patients were assessed at baseline, 3 and 6 months after Duodopa® treatment initiation using Unified Parkinson's Disease Rating Scale-Part III and IV (UPDRS-III and IV), Unified Dyskinesia Rating Scale (UdysRS), Beck Depression Inventory (BDI-II), Hamilton Anxiety Rating Scale (HAM-A) and Parkinson's Disease Quality of Life Questionnaire (PDQ-39). The caregivers were assessed, at the same time as the patients, using BDI-II, HAM-A, Caregiver Burden Inventory (CBI) and SF-36 Health Status Questionnaire. Six months after Duodopa® therapy, the scores of UPDRS-III and IV, UdysRS, BDI-II, HAM-A and PDQ-39 were significantly decreased (p < 0.01). After Duodopa® therapy, in caregiver group the scores of BDI-II, HAM-A and CBI were significantly decreased and the scores of SF-36 Health Status Questionnaire were significantly increased (p < 0.01). A reduction of anxiety after therapy correlated with mental status domains of SF-36 Health Status Questionnaire (r = 0.56). Overall, Duodopa® is effective even in the short time to improve the clinical conditions of PD patients and caregivers and their quality of life.

Original languageEnglish
Pages (from-to)2005-2014
Number of pages10
JournalJournal of Neurology
Volume265
Issue number9
DOIs
Publication statusPublished - Sep 2018

    Fingerprint

Keywords

  • Aged
  • Antiparkinson Agents/therapeutic use
  • Carbidopa/therapeutic use
  • Caregivers/psychology
  • Drug Combinations
  • Female
  • Humans
  • Levodopa/therapeutic use
  • Male
  • Middle Aged
  • Parkinson Disease/drug therapy
  • Prospective Studies
  • Quality of Life
  • Treatment Outcome

Cite this